The Invisible Patients in Clinical Trials

Explores how fragmented systems and blame culture slow progress in clinical research, and why collaboration and shared responsibility are vital for sustainable innovation.

Every year, thousands of people are ready and willing to join clinical trials. They have the motivation, the conditions under study, and the interest in contributing to medical progress. Yet many of them are never given the chance. Many potential participants never join our studies because of basic barriers such as geography, lack of awareness, or overly complex trial processes, making them “invisible” to research.

The problem is not a lack of interest. It is a lack of access. Some patients live too far from research sites. Others cannot afford to take time off work or arrange travel. Many simply never hear about the opportunities available to them. These hidden gaps in the system prevent our research from reflecting the full diversity of real-world patients. The gaps also slow progress, because trials take longer to enrol and sometimes fail altogether.

Solving this issue requires a shift in how we approach recruitment and design. We must build trials that meet patients where they are, not expect patients to overcome complex systems just to be seen. One part of that shift involves expanding clinical trial accessibility. We need to make it easier for people to find, understand, and join research opportunities in ways that work with their lives.

Clinical Trial Accessibility Starts with Awareness

A major reason people remain invisible is that they never hear about clinical trials in the first place. Many patients do not know that they could qualify. They may believe trials are only for people in big cities or for those already at major hospitals. This misconception keeps many willing volunteers out of the loop.

Improving awareness means starting in the right places. Community partnerships with local organizations, advocacy groups, and patient influencers can create trusted entry points that connect these patients to opportunities. Working together, we can provide information through channels that people already use and trust.

Language and literacy also matter. Trial listings and recruitment materials often use technical or formal language that feels distant and confusing. Instead, we should ensure communications are written clearly and shared in a variety of formats so patients feel informed and empowered to take the next step.

Online search tools are improving, but there is still work for us to do to boost clinical trial accessibility. Many patients struggle to navigate existing registries or cannot find trials that match their condition. Simplified discovery tools, using plain language, multiple languages, and intuitive interfaces, reduce friction and help patients find trials that are relevant to them.

Rethinking Clinical Trial Recruitment with Communities in Mind

The process of enrolling in a trial can feel overwhelming from the patient’s point of view. From long screening questionnaires to multiple site visits, each step adds another barrier for patients who are already stretched thin. Making this process simpler is one of the most effective ways we can improve clinical trial recruitment.

Clinical trial recruitment strategies should not rely solely on digital ads or hospital databases. Instead, engaging directly with communities helps to uncover untapped interest. Local events, faith-based outreach, and partnerships with cultural leaders can open doors that traditional outreach may miss.

Another approach is to use local ambassadors: individuals from within the community who can share information and answer questions in a personal way. People are more likely to trust someone who understands their background and speaks their language.

Trust also depends on transparency. Patients need to know what participation involves, how their data will be used, and how their voice will be respected. By offering this clarity early in the recruitment process, we can create an environment where patients feel safe and supported.

Hybrid Trial Models Expand Reach

Hybrid and decentralised trial models can bring research closer to patients by reducing travel demands, integrating local care providers, and leveraging technology. The flexibility of hybrid designs means that more patients, especially those in rural or underserved areas, can take part without putting their lives on hold.

Decentralised models are especially effective for chronic or rare conditions where patients may be spread across large areas. They also support working adults, caregivers, and those with mobility challenges. By removing the expectation that patients must come to the research site, trials become more inclusive by design.

To make hybrid trials work, technology must be accessible and easy to use. Devices, apps, and platforms should be designed with patients in mind. Support must be available to help them use these tools effectively. When done right, this model turns the patient’s home into a study site that fits into their day-to-day life.

Designing Trials for Real Lives

When designing a study, researchers should consider more than just medical endpoints. We should consider how the study fits into real human lives. That means thinking about transportation, caregiving duties, work schedules, and the emotional burden of participation.

Patient advisory boards can be a valuable tool here. These groups give us insight into what patients actually experience, allowing us to adjust protocols and materials to reduce friction. Co-designing parts of the trial with patients leads to better results, fewer dropouts, and stronger data.

Trial sites can also be selected with access in mind. Using community clinics, mobile units, or pharmacies expands the footprint of research into spaces people already use. Even small adjustments like evening appointments or child-friendly waiting areas can make a big difference.

Ultimately, every decision in trial planning affects who shows up and who stays. By making those decisions with patient realities in mind, we help uncover those who have long been overlooked.

Addressing the needs of invisible patients is not only a moral responsibility but also a scientific one. Let’s speak about creating more diverse and representative trials that lead to better data and outcomes.

Picture of Keith Berelowitz | Founder & CEO

Keith Berelowitz | Founder & CEO

Keith Berelowitz is the Founder of pRxEngage, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.


More

Explores how fragmented systems and blame culture slow progress in clinical research, and why collaboration and shared responsibility are vital

Reading time: 6mins

Participating in paid drug trials in the UK can be an eye-opening experience. Many people take part to support medical

Reading time: 7mins

Explore how engagement builds patient trust in clinical trials by focusing on connection, communication, and support throughout the patient journey.

Reading time: 5mins

Everyone deserves a say in healthcare’s future. pRxEngage helps you find your trial match, expanding access and giving you control to improve research for all.